{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:24:47Z","timestamp":1789885487881,"version":"4.0.1"},"reference-count":86,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,4,19]],"date-time":"2015-04-19T00:00:00Z","timestamp":1429401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Deregulated Hedgehog (Hh) signalling activity may be associated with a broad range of cancer types and hence has become an attractive target for therapeutic intervention. Although initial haematological interest focused on the therapeutic targeting of this pathway in chronic myeloid leukaemia), small molecule inhibitors targeting the Hh pathway are now being tested in a range of other myeloid disorders, including myelofibrosis, myelodysplasia and acute myeloid leukaemia. In this review we will evaluate the rationale for targeting of the Hh pathway in myeloid diseases and discuss the novel agents that have entered the clinical arena. We will discuss pre\u2010clinical models, emerging clinical trial data, and suggest how these targeted therapies may address current unmet medical needs. Finally, we will explore potential limitations of these therapies due to the emergence of secondary resistance mechanisms and speculate on future developments within this arena.<\/jats:p>","DOI":"10.1111\/bjh.13426","type":"journal-article","created":{"date-parts":[[2015,4,20]],"date-time":"2015-04-20T04:43:01Z","timestamp":1429504981000},"page":"323-335","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?"],"prefix":"10.1111","volume":"170","author":[{"given":"Alesia A.","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Haematology Guy's and St. Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology Guy's and St. Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[{"name":"Department of Haematology Guy's and St. Thomas\u2019 NHS Foundation Trust London UK"},{"name":"Department of Haematological Medicine King's College Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23857"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11889"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063226"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"s666","DOI":"10.1182\/blood.V122.21.666.666","article-title":"Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis [abstract]","volume":"122","author":"Bhagwat N.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-368142"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001599"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood.V120.21.1441.1441","article-title":"Evidence that activated hedgehog signaling predicts for poor clinical outcome in acute myeloid leukemia","volume":"120","author":"Campbell V.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2010.04.016"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.52"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2009.04.004"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.432302"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-359075"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.243"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1614"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.08.003"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2876"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1242\/dev.128.10.1717"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2503"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0258"},{"key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood.V122.21.1649.1649","article-title":"Treatment with hedgehog inhibitor, PF\u201004449913, attenuates leukemia\u2010initiation potential in acute myeloid leukemia cells","volume":"122","author":"Fukushima N.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2009.03.015"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-09-B192"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2005.01.010"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.319"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"s634","DOI":"10.1182\/blood.V124.21.712.712","article-title":"Phase 1b dose\u2010escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis","volume":"124","author":"Gupta V.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81268-4"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-08-0142"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.733"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1104655"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1622"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1182\/blood.V124.21.3612.3612","article-title":"Hh\/IGF\u20101R\/PI3K\/Akt\/MRP1 Pathway induce refractory acute myeloid leukemia and its targeting therapy","volume":"124","author":"Huang K.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-383752"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood.V114.22.1428.1428","article-title":"Combination of the hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells","volume":"114","author":"Irvine D.A.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-1958"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.9.17.12945"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","first-page":"s424","DOI":"10.1182\/blood.V118.21.424.424","article-title":"Phase 1 dose\u2010escalation study of PF\u201004449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies [abstract]","volume":"118","author":"Jamieson C.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2009.01.033"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(98)80117-2"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5268.1668"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1777"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.325_1188"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.98"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01111.x"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.36"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1684-6"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.20.4808"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-389692"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.30"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S21957"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0054"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-557298"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-30-8"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.595348"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.143"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.7.1802"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241703"},{"key":"e_1_2_9_58_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.e13520","article-title":"Effect of treatment with hedgehog inhibitor, PF\u201004449913, on leukemia\u2010initiation potential in acute myeloid leukemia cells","volume":"31","author":"Minami Y.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4676"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008824"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/287795a0"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.02.012"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-544411"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611682104"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0504337103"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2331"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.03.008"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404657"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4539.4539"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.294"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-208330"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.35"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.01.003"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/35077219"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604568103"},{"key":"e_1_2_9_76_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.tps6634","article-title":"Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome\u2010positive (Ph+) chronic myeloid leukemia in chronic phase (CML\u2010CP): design of CA180\u2010363, a phase II, open\u2010label randomized trial","volume":"30","author":"Trudel G.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1693608"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905360"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.028"},{"key":"e_1_2_9_81_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood.V122.21.53.53","article-title":"Expression of hedgehog pathway mediator Gli2 represents a clinically negative prognostic marker in acute myeloid leukemia and its inhibitor GANT61 exerts anti\u2010leukemic effects in\u00a0vitro","volume":"122","author":"Wellbrock J.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_9_82_1","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.V122.21.1533.1533","article-title":"Hedgehog pathway is deregulated in myelodysplastic syndrome progenitor bone marrow cells","volume":"122","author":"Xavier J.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07275"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1179386"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13283"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07737"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-439661"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13426","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T01:06:30Z","timestamp":1696035990000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,19]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/bjh.13426"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13426","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,19]]},"assertion":[{"value":"2015-04-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}